Compounded tirzepatide: is it legal, is it safe, how to read the vial

Compounded tirzepatide is a pharmacy-made injection labeled with the same active ingredient as Zepbound and Mounjaro, usually sold as a multi-dose vial instead of a pen. It was widely available while the brand was on the FDA’s shortage list. That ended in early 2025, and what is left is a narrow patient-specific exception. In 2026 the FDA and a federal appeals court moved further against routine copies.

Where compounded tirzepatide stands now

We found no final FDA decision on the April proposal as of November 2, 2026.

Is compounded tirzepatide legal?

Sometimes, within narrow limits that depend on who is compounding. The law lets compounders make copies of an approved drug freely only while that drug is in shortage, and the FDA’s April 2026 policy page confirms tirzepatide is on neither the shortage list nor the 503B bulks list.

Two kinds of compounders exist under federal law:

• 503A pharmacies are state-licensed pharmacies and physicians compounding for identified patients on individual prescriptions. They are overseen mainly by state boards of pharmacy.
• 503B outsourcing facilities register with the FDA, follow federal manufacturing standards and can make batches without a prescription for each one. In most cases they cannot compound from bulk ingredients unless the substance is on the bulks list or the drug is in shortage.

For a 503A pharmacy, a compounded product can avoid being a copy when it has a change that makes a significant difference for an individual patient, “as determined by the prescribing practitioner.” Pharmacy Times gives a documented allergy to an inactive ingredient, or a needed strength that is not sold, as examples. The FDA also says, as a general policy, that it does not intend to act against a compounder that “fills four or fewer prescriptions” of a copy in a calendar month.

Routine production does not qualify. In its September 2026 warning letter, the FDA objected to orders that had no prescriber determination at all, and to statements “repeated verbatim across many records.” It also raised concerns about pre-selected menu options for choosing a reason. That matters for any telehealth program offering the same checkbox reason to everyone. If you are told you need compounded tirzepatide, a fair question is what your specific clinical reason is, and whether it is written in your record.

The FDA’s safety warnings

The FDA says compounded drugs are not FDA-approved, and that it does not review them for safety, effectiveness or quality before they are sold. Its page on unapproved GLP-1 drugs, current as of October 1, 2026, raises these concerns:

• Dosing errors. Patients drew up the wrong amount and some clinicians miscalculated doses, in reports the FDA ties to compounded injectable semaglutide. Some cases required hospitalization. The agency also cites adverse events that may be linked to compounded semaglutide or tirzepatide prescribed beyond the label, including faster increases.
• Adverse event counts. As of May 31, 2026, the FDA had more than 730 reports tied to compounded tirzepatide and 990 tied to compounded semaglutide. It says these are likely underreported, since state-licensed pharmacies that are not outsourcing facilities do not have to report them.
• Multi-dose vials. The FDA recommends discarding a vial within 28 days of first use, even if medicine remains and even if the compounder says it lasts longer, and using a new sterile needle and syringe each time.
• Shipping. It has complaints of products arriving warm or with too few ice packs, and recommends not using any injectable GLP-1 that arrives warm.
• Fake labels. Some compounded semaglutide and tirzepatide carried the names of pharmacies that do not exist, or of real pharmacies that did not make them.
• Salt forms. Semaglutide sodium and acetate are “different active ingredients than are used in the approved drugs,” and the FDA knows of no lawful basis for using them. The page does not name tirzepatide salts, but the Zepbound and Mounjaro labels list the active ingredient as tirzepatide.

Sterility is a real-world issue too. A recall classified on October 8, 2026 covered compounded tirzepatide 18 mg/mL, 4 mL vials distributed nationwide, in 22 lots, because sterility could not be assured. The FDA rated it Class II. Mounjaro and Zepbound were not part of it.

Tirzepatide sold “for research purposes” or “not for human consumption” is neither compounded nor legal to use on people. The FDA says such products were falsely labeled, sold to consumers with dosing instructions, and are of unknown quality.

What to check on a compounded vial label

A pen does the measuring for you. A vial puts that on you, so read the label before you touch a syringe.

1. Concentration, in mg/mL. This sets your dose in units. FDA records show vials at 17 and 18 mg/mL, among others, and two vials can differ. A label showing only a total, such as “30 mg,” with no volume does not tell you the concentration.
2. Beyond-use date. Compounded products carry a beyond-use date. Even so, the FDA’s 28-day advice after first use applies.
3. Pharmacy name, address and state license. Check these against your state board of pharmacy. Spelling errors or a wrong address are FDA red flags.
4. Active ingredient as written. The approved labels say tirzepatide. A salt form is a reason to call the pharmacy.
5. Added ingredients. Vitamin B12, niacinamide and others appear in some formulations. Whatever is listed should match what the prescriber ordered.
6. Storage instructions and a lot number, so a problem can be traced and a recall can be checked.

If any of these are missing, or the package arrived warm, call the dispensing pharmacy before use.

Units per dose at example concentrations

An insulin syringe is marked in units, where 100 units equals 1 mL. To convert a dose, divide the mg by the concentration in mg/mL, then multiply by 100. The doses below are the six steps on the tirzepatide dosage chart; your prescriber sets which one applies. The concentrations are examples, so use the number on your own vial.

At 10 mg/mL, a 12.5 mg or 15 mg dose is more than a 1 mL syringe holds. At 30 mg/mL, one misread unit is a large share of a 2.5 mg dose. The calculator below does the arithmetic for any concentration, and the mg/mL to units converter handles other drugs.

How it compares with the brand

Lilly’s prices have narrowed the argument for compounding on cost. The tirzepatide cost guide lays out every route.

What about oral or sublingual tirzepatide?

No FDA-approved oral tirzepatide exists. Pills and drops are being compounded, but they have not been through clinical trials or FDA evaluation, so it is unclear how well they work or what a standard dose would be.

Who should not use it, and what to watch for

Every warning on the brand label applies to any product containing tirzepatide. That means no use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and none after a serious allergic reaction to tirzepatide or an ingredient. The tirzepatide side effects guide covers the warnings in full.

Two risks are specific to vials. The first is the dosing error the FDA keeps reporting: a 20 mg/mL vial drawn to 50 units delivers 10 mg, four times the starting dose. The second is contamination, since a multi-dose vial is entered again and again. Redness, swelling or pain at the injection site is worth reporting to your prescriber, and any problem with a compounded product can be reported to FDA MedWatch at 1-800-FDA-1088. The injection sites guide covers technique; the prescriber covers the dose.